Published in Lab Business Week, December 25th, 2005
Revenue for the third quarter of 2005 totaled approximately $224,000; in the comparable period in 2004, the company had no operating revenues. While the company has not yet completed its preparation of its third quarter financial statements, it currently estimates that its net loss for the period was approximately $3.3 - 3.6 million, or $0.16 - 0.18 per fully diluted share, compared to a net loss of $3,148,745 for the comparable period in 2004, or $0.22 per fully diluted share.
The company has had to delay the filing of its report on Form...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.